Previous 10 | Next 10 |
After at least one year, 50 participants on simufilam experienced a 3.2 point improvement in ADAS-Cog scores whereas another group of 50 participants saw a .2 decline (on average). Acetylcholinesterase inhibitors produce a result between these two points in most individuals after one ...
Recent research is claiming pivotal study data was falsified in order to bolster the amyloid hypothesis. This should have a positive impact on Alzheimer's programs based on other mechanisms. Anavex is one of them. A paper recently came out in Science magazine that ha...
July was the highest revenue generating month of 2022. The US hard to borrow equity market pushes revenues higher. Fixed income continues to see strong demand. Corporate bonds are in for an impressive 2022. Global securities finance revenues totalled $1.215 bln, ...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Shares of Cassava Sciences (NASDAQ: SAVA ) are erupting higher on the day, with SAVA stock up about 10% at the time of writing. At one point though, shares were up almost 20% in the session. Part of that exuberance ...
Cassava Sciences press release ( NASDAQ: SAVA ): Q2 GAAP EPS of -$0.48 misses by $0.06 . Cash Position - $197.2 Million of Cash and Cash Equivalents at June 30, 2022. Cognition Maintenance Study - Completion of Patient Enrollment is Expected Q4 2022. Phase 3 Pr...
Phase 3 Program - Over 400 Patients Are Now Enrolled in Our Phase 3 Clinical Studies. Open-label Study – Results of an Interim Analysis on the First 100 Patients Who Have Completed at Least 12 Months of Open-label Treatment with Simufilam Follow: Drug Appears ...
Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This report optimizes tradi...
CASSAVA SCIENCES INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Cassava Sciences, Inc. - SAVA CASSAVA SCIENCES INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips This article is excerpted from Tom Yeung’s Profit & Protection newsletter dated July 28, 2022. To make sure you don’t miss any of Tom’s picks, subscribe to his mailing list here . Sourc...
Clinical-stage biotech Cassava Sciences (NASDAQ:SAVA) responded to charges of research wrongdoing on Wednesday after it was reported that the U.S. Department of Justice had opened a criminal investigation into the company's experimental Alzheimer's treatment. According to Chie...
News, Short Squeeze, Breakout and More Instantly...
Cassava Sciences, Inc. (NASDAQ: SAVA) is one of today's top gainers. The company's shares have moved 24.9% on the day to $12.59. Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a...
A look at the top 10 most actives in the United States NVIDIA Corporation (NVDA) fell 6.6% to $117.99 on volume of 383,510,118 shares Aptevo Therapeutics Inc. (APVO) rose 73.4% to $0.581 on volume of 315,289,581 shares PROSHARES TRUST (SQQQ) rose 8.7% to $8.11 on volume of 173,682,364 sha...